Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Important Update

State/Territory-Coordinated Distribution of Sotrovimab

December 17, 2021

​Monoclonal Antibody Therapeutic Updates

The information below was posted on December 17, 2021. For current information regarding sotrovimab and other COVID-19 therapeutics distributed by the HHS, please visit the State/Territory-Coordinated Distribution of COVID-19 Therapeutics page.








In late November, the federal government paused shipment of the monoclonal antibody therapeutic sotrovimab in order to help ensure a more balanced portfolio of monoclonal antibody products and to allow more time to assess data regarding the effectiveness of sotrovimab against the Omicron variant.

Early in vitro data suggests sotrovimab retains activity against the Omicron variant. As such, we are actively preparing approximately 55,000 doses of sotrovimab for immediate allocation to your jurisdictions. Shipment of product will begin soon, and jurisdictions will see product arrive as early as Tuesday, December 21, 2021. 

Allocation of sotrovimab to state and territorial health departments was determined using the same methodology as before, which takes into account COVID-19 incidence rates and hospitalizations.

Please note that the federal government’s current supply of sotrovimab is extremely limited, and additional doses of the product will not be available until the week of January 3rd. We recommend that jurisdictions continue use of the bam/ete and REGEN-COV monoclonal antibody products while reserving sotrovimab for treatment of eligible outpatients at highest risk who are either:

  • diagnosed with a test that may identify a potential case of the Omicron variant (e.g., by S gene Target Failure in the ThermoFisher TaqPath assay); or
  • are present in local settings where reported prevalence of Omicron is  greater than 20%.

Until local prevalence of Omicron is greater than 20%, jurisdictions are encouraged to direct sotrovimab to sites that can provide IV treatment (within 48 hours of collection of a patient sample) to highest risk, eligible individuals diagnosed with a test that may identify a potential case of the Omicron variant.

Highest risk criteria for severe COVID-19 can be determined by local prioritization schemes, but criteria may include: age ≥ 65 years, major immune suppression (e.g., recently diagnosed hematologic malignancy, cancer chemotherapy, solid organ transplant on immune suppression), obesity with BMI >35-40 kg/m2, cardiovascular disease (including hypertension), pregnancy, poorly controlled diabetes, significantly reduced kidney function, COPD, stroke, and two or more risk factors.

Jurisdictions should also take into consideration the NIH COVID-19 Treatment Guidelines Panel’s Statement on prioritization when there are logistical or supply constraints.

Distribution Determinations for Sotrovimab: December 17, 2021

State/Territory Name

Abbreviation sotrovimab
(units = doses)

Alaska

AK

66

Alabama

AL

318

Arkansas

AR

372

American Samoa

AS

12

Arizona

AZ

1,644

California

CA

2,658

Colorado

CO

984

Connecticut

CT

1,002

District of Columbia

DC

108

Delaware

DE

276

Department of Defense

DD

96

Department of State

DoS

12

Florida

FL

1,050

Georgia

GA

816

Guam

GU

18

Hawaii

HI

66

Iowa

IA

774

Immigration and Customs Enforcement

ICE

12

Idaho

ID

180

Illinois

IL

3,288

Indian Health Service

IHS

180

Indiana

IN

2,160

Kansas

KS

726

Kentucky

KY

1,140

Louisiana

LA

228

Massachusetts

MA

1,800

Maryland

MD

384

Maine

ME

414

Michigan

MI

3,228

Minnesota

MN

1,374

Missouri

MO

1,338

Commonwealth of the Northern Mariana Islands

MP

72

Mississippi

MS

192

Montana

MT

132

North Carolina

NC

1,380

North Dakota

ND

168

Nebraska

NE

420

New Hampshire

NH

498

New Jersey

NJ

1,938

New Mexico

NM

504

Nevada

NV

378

New York

NY

4,242

Ohio

OH

3,888

Oklahoma

OK

648

Oregon

OR

318

Pennsylvania

PA

3,750

Puerto Rico

PR

42

Rhode Island

RI

384

South Carolina

SC

468

South Dakota

SD

198

Tennessee

TN

810

Texas

TX

2,694

Utah

UT

540

Virginia

VA

1,128

Veterans Health Administration

VHA

150

Virgin Islands

VI

6

Vermont

VT

156

Washington

WA

552

Wisconsin

WI

2,052

West Virginia

WV

492

Wyoming

WY

78

Totals

 

55,002

  • This page last reviewed: January 14, 2022